Stuttgart - Delayed Quote EUR

argenx SE (1AEA.SG)

635.00

+15.00

+(2.42%)

At close: January 31 at 3:46:36 PM GMT+1

Exploring High Growth Tech Stocks With Promising Potential

As global markets experience a surge, with U.S. stocks reaching new heights amid optimism over trade policies and AI advancements, growth stocks have notably outperformed their value counterparts, highlighting investor enthusiasm for innovation-driven sectors. In this dynamic environment, identifying high-growth tech stocks involves evaluating companies that can leverage technological advancements and strategic partnerships to capitalize on emerging market opportunities.

Simply Wall St. 2 days ago

ARGNF

ARGX
argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and

GlobeNewswire 19 days ago

ARGNF

ARGX
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl

GlobeNewswire 26 days ago

ARGNF

ARGX
Exploring High Growth Tech Stocks for January 2025

As we enter January 2025, global markets are navigating a landscape marked by fluctuating consumer confidence and mixed economic indicators, with major U.S. stock indexes experiencing moderate gains amidst a holiday-shortened trading week. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential and market adaptability, particularly as the technology-heavy Nasdaq Composite continues to show resilience despite recent...

Simply Wall St. 30 days ago

ARGNF

ARGX
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

Argenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements i

TipRanks last month

ARGNF

ARGX
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of

GlobeNewswire last month

ARGNF

ARGX
Three Stocks Estimated To Be Undervalued In December 2024

As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.

Simply Wall St. last month

SWEC-A.ST

SWEC-B.ST

ESRCF
Spotlight On High Growth Tech Stocks This December 2024

As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes.

Simply Wall St. last month

ARGNF

ARGX

GTK.NZ
argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wedn

GlobeNewswire 2 months ago

ARGNF

ARGX
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease

GlobeNewswire 2 months ago

ARGNF

ARGX
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)]

GlobeNewswire 2 months ago

ARGNF

ARGX
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

SHANGHAI & CAMBRIDGE, Mass., November 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP

Business Wire 2 months ago

ZLAB

ARGNF

ARGX
argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November: Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA. Jefferies London Healthcare Conference. Manageme

GlobeNewswire 2 months ago

ARGNF

ARGX
Three Value Stocks Priced Below Estimated Worth In November 2024

As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals...

Simply Wall St. 2 months ago

ARGNF

ARGX

GFL
High Growth Tech Stocks To Watch In November 2024

In a week marked by busy earnings reports and economic data releases, global markets saw major indices like the Nasdaq Composite and S&P MidCap 400 hit record highs before retreating, while small-cap stocks showed resilience compared to their larger counterparts. Amidst this backdrop of cautious optimism and mixed signals from the labor market, investors are keenly watching high-growth tech stocks that demonstrate strong fundamentals and potential for innovation-driven expansion.

Simply Wall St. 2 months ago

TIPSMUSIC.BO

TIPSMUSIC.NS

ARGNF
Argenx price target raised to $660 from $540 at Truist

Truist raised the firm’s price target on Argenx (ARGX) to $660 from $540 and keeps a Buy rating on the shares after its Q3 earnings beat. The company delivered 11th consecutive sequential growth quarter and the stock offers the most enviable I&I – inflammation and immunology – pipeline in the industry, with multiple data read-outs over the next 12-18 months, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan

TipRanks 2 months ago

ARGNF

ARGX
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced i

GlobeNewswire 3 months ago

ARGNF

ARGX
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at arg

GlobeNewswire 3 months ago

ARGNF

ARGX
Discover October 2024's Stocks Estimated To Be Trading Below Fair Value

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, identifying stocks that may be trading below their fair value can offer potential opportunities for those looking to capitalize on market inefficiencies.

Simply Wall St. 3 months ago

CLLNY

CLNXF

NONOF
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-up safety data that totals >8,000 patient years; no vaccinations required and no impact on human serum albumin levels Real-world data show more than 50 percent of gMG patients demonstrate substantial and sustained reduction i

GlobeNewswire 3 months ago

ARGNF

ARGX

Performance Overview

Return	1AEA.SG	BEL 20
YTD	+7.63%	+2.37%
1-Year	+80.40%	+18.72%
3-Year	+183.48%	+6.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

argenx SE (1AEA.SG)

Exploring High Growth Tech Stocks With Promising Potential

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks for January 2025

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Three Stocks Estimated To Be Undervalued In December 2024

Spotlight On High Growth Tech Stocks This December 2024

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

argenx to Participate at Upcoming Investor Conferences

Three Value Stocks Priced Below Estimated Worth In November 2024

High Growth Tech Stocks To Watch In November 2024

Argenx price target raised to $660 from $540 at Truist

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Performance Overview